Stool transplant plus antibody drug shows promise against recurrent c. diff in IBD patients
NCT ID NCT03829475
First seen Jan 04, 2026 · Last updated Jun 21, 2026 · Updated 27 times
Summary
This study tested whether combining a fecal microbiota transplant (FMT) with the drug bezlotoxumab could prevent repeat Clostridium difficile infections in people with inflammatory bowel disease (IBD). Sixty-one adults with at least two prior C. diff infections were randomly assigned to receive FMT plus bezlotoxumab or FMT plus a placebo. Participants were followed for three months to see if the infection came back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATORY BOWEL DISEASES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
fecal microbiota transplantation (FMT) plus bezlotoxumab (Zinplava)
What this could lead to
If it works, this combination could offer a more effective way to prevent repeat C. diff infections in people with inflammatory bowel disease.
What could go wrong
This is a small, early-phase study (61 participants) and results may not apply to everyone. The treatment involves infusing donor stool, which carries unknown infection risks.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.